An assessment of emerging molecular farming activities based on patent analysis (2002∼2006)
- 88 Downloads
The products of Plant Molecular Farming are recombinant proteins or their metabolic products. In this study, patent data was employed to assess industrial trend in the research and innovation process of Plant Molecular Farming within national and international context. The US Patent and Trade Organization (USPTO), the European Patent Office (EPO) issued a total of 585 patents covering Plant Molecular Farming from 2002 through 2006. By nationality, US inventors predominated as recipients of PMF patents, followed by Germany, Denmark, and Japan. The PMF patents were catagorized in five major areas of research namely pharmaceutical and nutraceuticals with 170 patents (31%) and plant expression tools and methods for alternative production systems with 169 patents (29%) were the dominating patent applications, followed by 102 patent claims associated with antibodies (17%), 71 patents of industrial molecules (12%), 48 patents of vaccines (8%), and finally 18 patents related to post-translational protein glycosylation (3%). The greatest proportion of patentees was of US origin (52%), and PMF associated patenting activities at the USPTO and EPO were dominated with 67% by private organizations.
Keywordsplant molecular farming recombinant patent analysis USPTO EPO
- 4.Science-technology Linkages in an Emerging Research Platform: The Case of Conbinatorial Chemistry and Biology. Electronic Working Paper No. 37. http://ideas.repec.org/p/dgr/umamer/1999020.html.
- 7.Oppenheim, C. (2000) Do patent citations count? pp. 405–432. In: B. Cronin and H. B. Atkins (eds.). The Web of Knowledge. Information Today, Medford, NJ, USA.Google Scholar
- 13.OECD (2006) Guidelines for the Licensing of Genetic Inventions (http://www.oecd.org/dataoecd/39/38/36198812.pdf).
- 14.OECD Compendium patent statistics (2003) http:// www.oecd.org/sti/ipr-statistics.
- 15.Beyond borders: A Global Perspective. The Ernst & Young Global Health Sciences. Biotechnology Report. http://www.ey.com/global/content.nsf/International/Biotechnology_Library_Beyond_Borders_2004.
- 16.Primer: Genome and Generic Research, Patent Protection and 21st Century Medicine. BIO Innovation Report. http://www.bio.org.
- 24.Arcand, F. and P. Arnison (2005) Development of Novel Protein-Production Systems and Economic Opportunities & Regulatory Challenges for Canada. http://www.cpmp2005.org/Plant-factories.aspx.
- 32.Blueprinting for the Development of Plant Derived Vaccines for the Poor in Developing Countries. http://www.biodesign.asu.edu.
- 37.Commandeur, U., R. M. Twyman, and R. Fischer (2003) The biosafety of molecular farming in plants. AgBiotech Net 5: 1–9.Google Scholar
- 40.Hood, E. E. and J. A. Howard (2002) Plants as Factories for Protein Production. Kluwer Academic Publishers, The Netherlands.Google Scholar
- 41.Woodard, S. L., J. M. Mayor, M. R. Bailey, D. K. Barker, R. T. Love, J. R. Lane, D. E. Delaney, J. M. McComas-Wagner, H. D. Mallubhotla, E. E. Hood, L. J. Gangott, S. E. Tichy, and J. A. Howard (2003) Maize-derived bovine trypsin: Characterization of the first large-scale, commercial protein from transgenic plants. Biotechnol. Appl. Biochem. 38: 123–130.CrossRefGoogle Scholar
- 42.Chargelegue, N. D., P. M. W. Drake, P. Obregon, and J. K. Ma (2005) Production of secretory IgA in transgenic plants. pp. 159–169. In: R. Fischer and S. Schillberg (eds.). Molecular Farming: Plant-Made Pharmaceuticals and Technical Proteins. Wiley-VCH, Weinheim, Germany.Google Scholar